SMFR News and Press, Sema4 Holdings Corp.

Sema4 Holdings ( NASDAQ: SMFR ) rose ~7% after the company said it has its changed name and ticker symbol and issued higher Y/Y 2022 revenue guidance. SMFR changed its name to GeneDx Holdings, with the ticker symbol of WGS. The class A shares will begin trading on Nasdaq under the...

Company expects to exceed 2022 revenue target with strong momentum to deliver continued growth in 2023 combining GeneDx and Centrellis ® platforms Company’s common stock will trade on the Nasdaq under new ticker “WGS” effective January 10, 2023 STAMFO...

STAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the company will participate in the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco. Katherine Stueland , President and Chief Executive Officer, will del...

Summary Sema4's restructuring plan has a number of potential downsides that could affect the company's cash position in the coming few quarters. The booting of the CEO signals the start of a strategic focus on short-term survival away from long-term growth. Even if management succee...

STAMFORD, Conn., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced the results of a new study on mitochondrial diseases in newborns. The findings support the addition of mitochondrial DNA (mtDNA) testing to rapid exome sequencing, showing it ca...

Sema4 Holdings Corporation (SMFR) Q3 2022 Earnings Conference Call November 14, 2022, 08:30 ET Company Participants Joel Kaufman - VP, Finance & Corporate Development Katherine Stueland - CEO & Director Kevin Feeley - SVP, Operations & CFO Confe...

Sema4 press release ( NASDAQ: SMFR ): Q3 GAAP EPS of -$0.20 beats by $0.10 . Revenue of $83.23M (+92.8% Y/Y) beats by $15.49M . Adjusted gross margin in the third quarter of 2022 was 20%, with the pediatric and rare disease franchise generating an adjusted gros...

Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing and analysis and data-driven insights from Centrellis ® 19% pro forma 1 volume growth vs. 3Q 2021 and 21% pro forma 1 ...

Sema4 ( NASDAQ: SMFR ) is scheduled to announce Q3 earnings results on Friday, November 11th, after market close. The consensus EPS Estimate is -$0.16 and the consensus Revenue Estimate is $67.74M (+56.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward...

STAMFORD, Conn., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), a health insights company, today announced it will release financial results for the third quarter of 2022 before the market opens on Monday, November 14, 2022. On the same day, Katherine Stueland , Chief Execu...